Tyra Biosciences has launched the SURF302 trial for intermediate-risk non-muscle invasive bladder cancer, testing a new therapeutic approach in an area with per

Tyra Biosciences has launched the SURF302 trial for intermediate-risk non-muscle invasive bladder cancer, testing a new therapeutic approach in an area with persistent treatment challenges. The study adds to Tyra’s broader push in urologic cancers.